



Journal of Pediatric Endocrinology and Metabolism **Information for Authors**

- 1. Scope and general policies of the Journal**
- 2. Ethical conduct of research**
- 3. Submission of manuscripts**
- 4. Preparation of manuscripts**
- 5. Post-acceptance**

1. Scope and general policies of the Journal

The *Journal of Pediatric Endocrinology and Metabolism (JPEM)* is a peer-reviewed journal which publishes cutting-edge articles on clinical investigations in pediatric endocrinology and basic research. *JPEM* is the only international journal dedicated exclusively to endocrinology in the neonatal, pediatric and adolescent age groups. *JPEM* is a high-quality journal dedicated to pediatric endocrinology in its broadest sense, which fills a gap at a time of rapid expansion in the field of endocrinology.

JPEM is issued monthly, and it is published in print and electronically. *JPEM* publishes only English-language articles in the following categories:

- Research Articles – Reports of original research.
- Reviews and Mini Reviews – Systematic, narrative, and focused reviews. Review articles are normally published by invitation, but suggestions to the Editors are welcome.
- Opinion Papers and Editorials
- Point/Counterpoint Papers
- Short Communications
- Case Reports
- Letters to the Editor and Replies
- Guidelines and Recommendations

Submissions in the following fields are welcomed:

- Pediatric Endocrinology
- Pediatric Diabetes and Obesity
- Inherited Metabolic Diseases
- Vitamin D Deficiency
- Neonates/Neonatal Screening
- Hormonal Disorders and Therapy
- Thyroid/Thyroid Disorders
- Bone Metabolism and Growth Impairment
- Cancer Diagnostics
- Puberty
- Sex Disorders and Infertility

Peer review *JPEM* is a single-blind journal. Manuscripts are reviewed anonymously by at least two independent reviewers selected by the Editors.

Turnaround times *JPEM* aspires to notify authors about the review decision within 3-4 weeks from submission date. Revised manuscripts should be returned within 6 weeks. Accepted articles are published online within 4 weeks after acceptance.

Rejection of manuscripts Manuscripts dealing with subjects that have been well studied in the literature, and that do not resolve questions raised by previous studies, or manuscripts that are statistically underpowered, are likely to be rejected without peer re-view. This applies in particular to studies of genetic associations, which will be considered only if they contribute new insights and are statistically valid according to generally accepted criteria. Articles which are likely to affect the choice, performance or interpretation of clinical tests will be favored over those which do not, and animal or cell-culture studies need to justify their eligibility. Reporting of negative results must be justified by prior evidence that a positive result would be expected. Manuscripts are also returned to authors if they do not comply with the Information for Authors (e.g., if the number of words allowed for a certain article type will be exceeded).

Unpublished material Submission of a manuscript to *JPEM* implies that the work described has not been published previously, except in the form of an abstract, academic thesis or lecture; that it is not under consideration for publication elsewhere; that publication of the work is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out; and that, if accepted, it will not be published elsewhere, in English, German, or in any other language, without the written consent of the Publisher.

Appeals Manuscripts that have been declined for publication will be reconsidered only at the discretion of the editor(s). Authors who wish to request reconsideration of a previously rejected manuscript must do so in written form with a rebuttal emailed to the journal editorial office. Authors should explain in detail the reasons why they believe the manuscript should be reconsidered. If the rebuttal is accepted, the author will be asked to re-submit. The new manuscript will receive a new ID and submission date and then undergo peer review.

2. Ethical conduct of research

For information on plagiarism, please refer to [COPE Committee on Publication Ethics](#). Please note that *JPEM* uses the check program "iThenticate" to assess for potential overlap in prior publication(s). Any previously published material must be referenced appropriately in the manuscript.

Informed consent The protection of privacy is a legal right that must not be infringed without individual informed consent. In cases where the identification of personal information is necessary for scientific reasons, authors should obtain full documentation of informed consent, including written permission from the patient or their legal guardians prior to inclusion in the study. The following (or similar) statement should be included in the Materials and methods section: Informed consent was obtained from all individuals included in this study.

Authorization for the use of human subjects Manuscripts containing information related to human use should clearly state that the research complies with all relevant national regulations and institutional policies and has been approved by the authors' Institutional Review Board or any equivalent Committee. Copies of the guidelines and policy statements must be available for review by the Managing Editor if necessary. The editors reserve the right to seek additional information or guidance from reviewers on any cases in which concerns arise. All investigations with human subjects must have been conducted by following the tenets of the [Declaration of Helsinki](#), what is more authors must identify the committee or review board approving the experiments, and provide a statement indicating approval of the research. The following (or similar) statement should be included in the Methods section: Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the authors' institutional review board or equivalent committee.

Authorization for the use of experimental animals Manuscripts containing information related to animals use should clearly state that the research has complied with all relevant national regulations and institutional policies and has been approved by the authors' institutional review board or equivalent committee. Copies of the guidelines and policy statements must be available for review by the Managing Editor if necessary. The editors reserve the right to seek additional information or guidance from reviewers on any cases in which concerns arise. The research using animal subjects should be conducted according to the Principles of Laboratory Animal Care and similar documents (e.g. [NIH](#)). For manuscripts reporting experiments on live vertebrates or higher invertebrates, authors must identify the committee approving the experiments, and must confirm that all experiments were performed in accordance with relevant regulations. The following (or similar) statement should be included in the Methods section: Ethical approval: The research related to animals use has been complied with all the relevant national regulations and institutional policies for the care and use of animals.

If the manuscript does not contain any study that requires human or animal ethical approval, the following statement should be included in the Methods section: Ethical approval: The conducted research is not related to either human or animals use.

Conflict of interest and author contributions A conflict of interest for a given manuscript exists when a participant in the peer review and publication process – author, reviewer, and editor – has ties to activities that could inappropriately influence his or her judgment, regardless of whether judgment is, in fact, affected. Financial relationships with industry (for example, employment, consultancies, stock ownership, honoraria, expert testimony), either directly or through immediate family, are usually considered the most important conflicts of interest. However, conflicts can occur for other reasons, such as financial support of the study, ties to health insurance, politics or other stakeholders, personal relationships, academic competition, and intellectual passion.

To ensure fair and objective decision-making, authors must declare any associations that pose a conflict of interest (financial, personal or professional) in connection with the manuscript under evaluation. This must be declared during the submission process and also at the end of the manuscript. If you have no declaration to make, please insert *None declared*. The below mentioned statement should be included before the Reference section (or after the Acknowledgments section, if applicable). Authors must also declare responsibility for the entire content of the manuscript and may declare individual contributions of each author, if applicable.

Acknowledgments: (If applicable).

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Declaration or None declared.

Employment or leadership: Declaration or None declared.

Honorarium: Declaration or None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Copyright Manuscripts are accepted on condition of transfer of copyright (for U.S. government employees: to the extent transferable) to the publisher. Once the manuscript has been accepted, it may not be published elsewhere without the consent of the copyright holders.

Note for authors of NIH-funded research De Gruyter acknowledges that the author of a US-agency-funded article retains the right to provide a copy of the final manuscript to agency upon acceptance for publication or thereafter, for public archiving in PubMed Central 12 months after publication in *JPEM*. Note that only the accepted author's version of the manuscript, not the PDF file of the published article, may be used for NIH archiving.

3. Submission of manuscripts

Please submit manuscripts exclusively online at: <https://mc.manuscriptcentral.com/JPEM>

4. Preparation of manuscripts

Language Manuscripts should be written in clear and concise English. Please have your text proofread by a native speaker or professional language service before you submit it for consideration. At proof stage, only minor changes other than corrections of printers' errors are allowed.

Cover letter Each manuscript should be accompanied by a cover letter containing a brief statement by the authors describing the novelty and importance of their research.

General format and length Type the manuscript (including table legends, figure legends and references) double-spaced using 12 pt font size and 1 inch margins. Number all pages. Do not use footnotes in the text, use parentheses instead.

When you submit your work, please ensure the following:

- The manuscript is complete and uploaded correctly. (The HTML version and the PDF file generated from the submitted files must be approved.)
- The title page contains the full title, short title, the full names of all authors (personal name, middle initials, family name), and the full address and the academic title of the corresponding author. The title page should also report the word count, the number of tables and figures, and whether the submission includes any supplemental material.
- All Figures and Tables have been uploaded and appear correctly at the end of the PDF.
- Abstract, Keywords, List of Abbreviations, Tables and Figures, and captions and legends are included.
- Manuscript is spell-checked and within the word limit for the type of article.
- References are in the correct format (Vancouver style) and cited sequentially in the text.
- References mentioned in the reference list are cited in the text and vice versa.
- Ethical approval is obtained and mentioned in the text.
- Numbers in the text, tables, or figures use decimal points, not commas.
- Supplier names, incl. city and country, are provided for reagents and apparatus reported in the manuscript.

General format and length of the types of articles accepted for submission

	Word count	Word count in abstract/structured (S), unstructured (U)	Number of keywords	Number of Tables & Figures	Number of references	Article
Research Article	3500	250, S*	3-6	8	50	Structured into Introduction, Materials (Subjects) and methods, Results, Discussion
Review Article	6000	200, U/S **	3-6	8	150	Structured
Mini Review	3500	200, U/S **	3-6	4	40	Structured
Opinion Paper	3500	250, U/S**	3-6	2	40	Structured
Point & Counterpoint	1500	200, U	3-5	2	15	Structured or unstructured
Short Communication	1500	200, S*	3-5	4	15	Abstract & unstructured text; Materials & methods are described in the legends to Figures and Tables
Case Report	1500	150, U/S***	3	2	10	Structured into Introduction, Case presentation, Discussion, Learning points (please give up to 2-5 bullet points)
Letter to the Editor & Reply	1200	n/a	3-5	2	10	Unstructured
Guidelines and Recommendations	3500	250, U	3-6	6	40	Structured
Editorial	1500	n/a	n/a	1	10	Structured or unstructured

*Background, Methods, Results, Conclusions; ** Background, Content, Summary and Outlook; *** Background, What is new? Case presentation, Conclusions.

Studies dealing with diagnostic accuracy Please refer to the 2015 Standards for Reporting of Diagnostic Accuracy checklist ([STARD](#)).

Systematic Reviews and Meta-Analyses of randomized controlled trials Please refer to the Preferred Reporting Items for Systematic Reviews and Meta- Analyses statement ([PRISMA](#)). Authors must include a

suitable PRISMA flow chart in their submission. The flow diagram depicts the flow of information through the different phases of a systematic review. A template of the PRISMA flow diagram is available [here](#) as a PDF and Word document.

Case Reports Please refer to the The CARE Guidelines: Consensus-based Clinical Case Reporting Guideline Development (**CARE**). Case Reports must contain an Abstract, Introduction, the Case Description, Discussion, and 2-5 bullet points as Learning Points. The Abstract must contain up to 3-5 bullet points “What is new?” Case Reports which are a mere description of a clinical case and do not contribute innovative findings to the literature, will be rejected.

References Adhere strictly to the reference style of the Journal (Vancouver; recommendations of the “International Committee of Medical Journals Editors”; see [Reference Style](#)). All references mentioned in the Reference list must be mentioned in the text, and vice versa. List and number the references consecutively in the order that they appear in the text, including Tables and Figures. In the text, identify references by Arabic numerals in [parentheses]. Italic and boldface font type in the Reference section is not allowed. List all authors; if the number is 7 or more, list the first 6 names followed by et al. Identify authors by last name first, followed by up to 2 initials, without periods, indicating the authors’ first name. Only the first name of the title is capitalized, as well as proper names within the title. Journal names are abbreviated as indicated in PubMed and in the Web of Knowledge ([NIH.Linkout.Journals](#); [Web of Knowledge](#)), without periods. After the abbreviated journal name, give the year of publication, followed by a semicolon, volume number (but no issue number), followed by a double colon, and the page numbers, with the last page number in shortened format. Meeting abstracts may be cited only if published in journals. Unpublished observations and personal communications are cited only in the text. Correct linking of the references depends on strict adherence to Journal style.

- **Articles in journals:** Alba P, Mitre N, Feldt M. More than one way to skin a thyroid. Managing pediatric hypothyroidism with weekly intramuscular levothyroxine. *J Pediatr Endocrinol Metab* 2016;29:745–8.
- **Articles in journals with 6 or more authors:** Klein K, Yang J, Aisenberg J, Wright N, Kaplowitz P, Lahlou N, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. *J Pediatr Endocrinol Metab* 2016;29:1241–8.
- **Articles ahead of print:** Analysis of growth hormone receptor gene expression in tall and short stature children. Pagani S, Radetti G, Meazza C, Bozzola M. *J Pediatr Endocrinol Metab* 2017 Mar 16. doi: 10.1515/jpem-2016-0355. [Epub ahead of print].
- **Articles in online only journals:** Labandeira CC, Kustatscher E, Wappler T. Floral assemblages and patterns of insect herbivory during the permian to triassic of Northeastern Italy. *PLoS One* 2016 Nov 9;11:e0165205.
- **Editorial:** Arélin M, Beblo S. Newborn screening of metabolic disorders. [Editorial] . *J Pediatr Endocrinol Metab* 2016;29:1-3.
- **Letter to the Editor:** Weykamp C, Kuypers A, Bakkeren D, Franck P, Loon Dv, Gunnewiek JK, et al. Creatinine, Jaffe, and glucose: another inconvenient truth [Letter]. *Clin Chem Lab Med* 2015;53:e347-9.
- **Supplements:** Ploder M, Schroecksadel K, Spittler A, Neurauter G, Roth E, Fuchs D. Moderate hyperhomocysteinemia in trauma and sepsis indicates poor survival. *Clin Chem Lab Med* 2009;47:Suppl:S187.
- **Books and Monographs:** Kahn CR, Weir GC, editors. *Joslin’s diabetes mellitus*, 13th ed. Philadelphia: Lea and Febiger, 1994:1068.
- **Chapters in Books:** Karnofsky DH, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. *Evaluation of chemotherapeutic agents*. New York: Columbia University Press, 1949:191–205.
- **Website:** World Health Organization. WHO information for laboratory diagnosis of pandemic (H1N1) 2009 virus in humans update. Available at: http://www.who.int/csr/resources/publications/swineflu/WHO_Diagnostic_RecommendationsH1N1_20090521.pdf. Accessed: 6 Nov 2009.

Tables Number Tables consecutively using Arabic numerals. Provide a short descriptive title, column headings, and (if necessary) footnotes to make each Table self-explanatory. In the footnote, refer to information within the Table with superscript lowercase letters, and do not use special characters or numbers. Separate units with a comma and use parentheses or square brackets for additional measures (e.g., %, range, etc). Refer to Tables in the text as Table 1, etc. Use Table 1 (boldface), etc. in the title of the Table.

Figures

General requirements: All illustrations must be of reproduction-ready quality. They will be reduced in size to fit, whenever possible, the width of a single column. Lettering of all Figures within the article should be uniform in style (preferably a sans serif typeface like Helvetica) and of sufficient size (ca. 10 pt.). Uppercase letters A, B, C, etc. should be used to identify parts of multi-part Figures. In the legend, these letters are included in parentheses. Cite all Figures in the text in numerical order. Indicate the approximate placement of each Figure. Do not embed Figures within the text body of the manuscript.

Halftone figures and line drawings: Figures should have a minimum resolution of 300 dpi (halftone figures) and 1200 dpi (line drawings) and be of good contrast. Faint shading may be lost upon reproduction. When drawing bar graphs, use patterning instead of grayscales.

Color plates: Authors are encouraged to submit illustrations in color if necessary for the scientific content of their work. Publication of color Figures is provided free of charge both in online and print editions.

Figure legends: Provide a short descriptive title and a legend, either below the Figure, in the main text, or on separate pages, to make each Figure self-explanatory. Explain all symbols used in a Figure. Remember to use the same abbreviations as in the text body.

Videos: Authors are encouraged to submit videos accompanying the article as Supplemental Material.

Supplemental material You may submit Supplemental material, i.e. additional tables, figures, videos, appendices or other additional material (e.g. references) that exceeds the limitation of the article and/or illustrates the contents of your article. Supplemental material should be uploaded as separate file(s) during submission. Within the text, Supplemental material must be cited consecutively and be referred to as Supplemental material (e.g. see Supplemental Material, Figure 1, or Supplemental Figure 1). Supplemental material is subject to peer review as part of the manuscript. If the manuscript is accepted and the Supplemental material is posted online, it will be referenced in the article of the printed version together with the URL where it can be found.

Nomenclature Follow the rules of the IUPAC-IUB Commission on Biochemical Nomenclature, as indicated in [IUB Biochemical Nomenclature and Related Documents](#). Enzyme names should be in accordance with the recommendations of the [IUPAC-IUB Commission on Biochemical Nomenclature](#), 1978, as in Enzyme Nomenclature, published by Academic Press, New York, 1992. Genotypes should be given in italics, phenotypes should not be italicized. Indicate the gene symbol and gene name as approved by the [HUGO Gene Nomenclature Committee](#). Nomenclature of bacterial genetics should follow Damerec et al. Genetics 1966; 54:61–76 ([Damerec et al.](#)).

Permissions It is the authors' responsibility to obtain permission to reproduce original or modified material that has been previously published elsewhere.

5. Post-acceptance

Proofs The corresponding author of an article will receive the proofs in electronic form to check for editing and type-setting accuracy. Major changes to the article as accepted for publication will not be considered at this stage, unless the authors pay for these changes.

Offprints The electronic files of typeset articles in Adobe Acrobat PDF format are provided free of charge; corresponding authors receive an e-mail notification that their article has been published online. Paper offprints can be ordered in addition; an offprint order form will accompany the page proofs and should be completed and returned with the corrected proofs immediately if offprints are requested.

Open Access policy If your manuscript is accepted, open access publication is available for authors who wish to make their article freely available on De Gruyter Online. Authors choosing to publish open access pay an article processing charge. All articles undergo peer review and will be accepted for publication based on the quality of their scientific contribution. Choosing open access publication has no influence on the peer review or acceptance process. For more information on De Gruyter's open access policies please visit:

<http://www.degruyter.com/dg/page/577/open-access-policy>

Please contact the Editorial Office with any further questions:

Simone Sporn, E-mail: JPem.editorial@degruyter.com